Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Holding IONS?
Track your performance easily
Ionis Pharmaceuticals (IONS) Ownership Overview
0.76% Insiders
36.51% Mutual Funds
1.95% Other Institutional Investors
14.64% ETFs
46.15% Public Companies and
Individual Investors
The ownership structure of Ionis Pharmaceuticals (IONS) stock is a mix of institutional, retail, and individual investors. Approximately 53.10% of the company’s stock is owned by Institutional Investors, 0.76% is owned by Insiders, and 46.15% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Jun 20, 2024 | Spencer Berthelsen Director | xxxxxxxxxxxxx | $644640 |
| May 07, 2024 | Joseph Klein Director | xxxxxxxxxxxxx | $256243 |
| Feb 16, 2024 | Brett Monia Ceo,director | xxxxxxxxxxxxx | $17218 |
| Feb 02, 2024 | Eric Swayze Evp Research | xxxxxxxxxxxxx | $560196 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Jun 30, 2024 | xxxxxxxxxxxxx | $228768 | |
| Jun 30, 2024 | xxxxxxxxxxxxx | $298446 | |
| Jun 30, 2024 | xxxxxxxxxxxxx | $64866451 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 13,038,379 | Institution | 8.27% | 505,367,570 | |
| 11,625,924 | Institution | 7.37% | 450,620,814 | |
| 11,367,622 | Institution | 7.21% | 440,609,029 | |
| 4,710,416 | Institution | 2.99% | 182,575,724 | |
| 4,696,200 | Institution | 2.98% | 182,024,712 | |
| 4,258,588 | Institution | 2.70% | 165,062,871 | |
| 3,454,676 | Institution | 2.19% | 133,903,242 | |
| 2,954,743 | Institution | 1.87% | 114,525,839 | |
| 2,324,474 | Institution | 1.47% | 90,096,612 | |
| 2,263,877 | Institution | 1.44% | 87,747,873 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 11,625,924 | Institution | 7.37% | 450,620,814 | |
| 11,367,622 | Institution | 7.21% | 440,609,029 | |
| 4,710,416 | Institution | 2.99% | 182,575,724 | |
| 4,696,200 | Institution | 2.98% | 182,024,712 | |
| 2,954,743 | Institution | 1.87% | 114,525,839 | |
| 2,324,474 | Institution | 1.47% | 90,096,612 | |
| 1,743,479 | Institution | 1.11% | 67,577,246 | |
| 1,537,197 | Institution | 0.97% | 59,581,756 | |
| 1,534,013 | Institution | 0.97% | 59,458,344 | |
| 1,313,675 | Institution | 0.83% | 50,918,043 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 4,500,444 | Institution | 2.85% | 180,287,787 | |
| 3,552,597 | Institution | 2.25% | 142,317,036 | |
| 2,356,941 | Institution | 1.49% | 94,419,056 | |
| 2,192,013 | Institution | 1.39% | 84,151,379 | |
| 1,959,321 | Institution | 1.24% | 78,490,399 | |
| 1,343,141 | Institution | 0.85% | 52,060,145 | |
| 944,467 | Institution | 0.60% | 36,607,541 | |
| 794,663 | Institution | 0.50% | 30,801,138 | |
| 761,424 | Institution | 0.48% | 29,231,067 | |
| 513,101 | Institution | 0.33% | 19,887,795 |
FAQ
Who Owns Ionis Pharmaceuticals (IONS)?
According to the latest TipRanks data, approximately 1.95% of the company's stock is held by institutional investors, 0.76% is held by insiders, and 46.15% is held by retail investors.
What percentage of Ionis Pharmaceuticals (IONS) stock is held by institutional investors?
According to the latest TipRanks data, approximately 1.95% of Ionis Pharmaceuticals (IONS) stock is held by institutional investors.
What percentage of Ionis Pharmaceuticals (IONS) stock is held by retail investors?
According to the latest TipRanks data, approximately 46.15% of Ionis Pharmaceuticals (IONS) stock is held by retail investors.
Who owns the most shares of Ionis Pharmaceuticals (IONS)?
Vanguard owns the most shares of Ionis Pharmaceuticals (IONS).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.